Sustained Correction of a Murine Model of Phenylketonuria following a Single Intravenous Administration of AAVHSC15-PAH
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy - Methods & Clinical Development
- Vol. 17, 568-580
- https://doi.org/10.1016/j.omtm.2020.03.009
Abstract
No abstract availableFunding Information
- Homology Medicines
This publication has 58 references indexed in Scilit:
- Immune responses to AAV vectors: overcoming barriers to successful gene therapyBlood, 2013
- White matter integrity and executive abilities in individuals with phenylketonuriaMolecular Genetics and Metabolism, 2013
- CpG-depleted adeno-associated virus vectors evade immune detectionJCI Insight, 2013
- Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU)Molecular Genetics and Metabolism, 2011
- Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levelsAging Cell, 2009
- Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuriaProceedings of the National Academy of Sciences of the United States of America, 2008
- Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal miceGenetic Vaccines and Therapy, 2008
- Correction of Murine PKU Following AAV-mediated Intramuscular Expression of a Complete Phenylalanine Hydroxylating SystemMolecular Therapy, 2008
- ThePAH gene, phenylketonuria, and a paradigm shiftHuman Mutation, 2007
- High-Level Transgene Expression in Nonhuman Primate Liver with Novel Adeno-Associated Virus Serotypes Containing Self-Complementary GenomesJournal of Virology, 2006